{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:39:38Z","timestamp":1763037578605,"version":"3.37.3"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["COVID19-8900-06"],"award-info":[{"award-number":["COVID19-8900-06"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG063913"],"award-info":[{"award-number":["RF1AG063913"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>A number of studies have reported the association between the use of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-II receptor blocker (ARB) medications and the occurrence or severity of coronavirus disease 2019 (COVID-19). Published results are inconclusive, possibly due to differences in participant comorbidities and sociodemographic backgrounds. Since ACEI and ARB are frequently used anti-hypertension medications, we aim to determine whether the use of ACEI and ARB is associated with the occurrence and severity of COVID-19 in a large study of US Veterans with hypertension.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Data were collected from the Department of Veterans Affairs (VA) National Corporate Data Warehouse (VA-COVID-19 Shared Data Resource) between February 28, 2020 and August 18, 2020. Using data from 228,722 Veterans with a history of hypertension who received COVID-19 testing at the VA, we investigated whether the use of ACEI or ARB over the two years prior to the index date was associated with increased odds of (1) a positive COVID-19 test, and (2) a severe outcome (hospitalization, mortality, and use of intensive care unit (ICU) and\/or mechanical ventilation) among COVID-19-positive patients. We used logistic regression with and without propensity score weighting (PSW) to estimate the odds ratio (OR) and 95% confidence interval (95% CI) for the association between ACEI\/ARB use and a positive COVID-19 test result. The association between medication use and COVID-19 outcome severity was examined using multinomial logistic regression comparing participants who were not hospitalized to participants who were hospitalized, were admitted to the ICU, used a mechanical ventilator, or died. All models were adjusted for relevant covariates, including demographics (age, sex, race, ethnicity), selected comorbidities, and the Charlson Comorbidity Index (CCI).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The use of ACEI significantly decreased the odds of a positive COVID-19 test among Veterans with hypertension (OR = 0.917, (0.887, 0.948) and OR = 0.926, (0.894, 0.958) with PSW). The use of ACEI, but not of ARB, was also associated with significantly increased odds of using mechanical ventilators (OR = 1.265, (1.010, 1.584) and OR = 1.210, (1.053, 1.39) with PSW) among all COVID-19 inpatients compared to outpatients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In this study of Veterans with hypertension, ACEI was significantly associated with decreased odds of testing positive for COVID-19. With the exception of the association of ACEI with a small non-clinically-important increase in the odds of using mechanical ventilators, neither ACEI nor ARB was found to be associated with clinical severity or mortality among COVID-19-positive Veterans. The results of this study need further corroboration and validation in other cohort samples outside the VA.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0248652","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:33:26Z","timestamp":1616088806000},"page":"e0248652","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension"],"prefix":"10.1371","volume":"16","author":[{"given":"Mingfei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ndindam","family":"Ndiwane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle B.","family":"Orner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brant","family":"Mittler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Berlowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis E.","family":"Kazis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7463-3295","authenticated-orcid":true,"given":"Weiming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"13","key":"pone.0248652.ref001","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Z Wu","year":"2020","journal-title":"JAMA"},{"issue":"18","key":"pone.0248652.ref002","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"WJ Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248652.ref003","doi-asserted-by":"crossref","first-page":"100044","DOI":"10.1016\/j.ijchy.2020.100044","article-title":"Prevalence and control rates of hypertension in the USA: 2017\u20132018","volume":"6","author":"MD Chobufo","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"issue":"7","key":"pone.0248652.ref004","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1\u20137: novel therapeutic targets","volume":"11","author":"F Jiang","year":"2014","journal-title":"Nature Reviews Cardiology"},{"issue":"7","key":"pone.0248652.ref005","article-title":"Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Y Wan","year":"2020","journal-title":"Journal of Virology"},{"key":"pone.0248652.ref006","doi-asserted-by":"crossref","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis","volume":"158","author":"X Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"pone.0248652.ref007","article-title":"The effect of prior ACEI\/ARB treatment on COVID-19 susceptibility and outcome: A systematic review and meta-analysis","author":"J Xu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0248652.ref008","article-title":"Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis","author":"X Liu","year":"2020","journal-title":"Clin Cardiol"},{"issue":"10","key":"pone.0248652.ref009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: A systematic review and meta-analysis of 28,872 patients","volume":"22","author":"R Baral","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"pone.0248652.ref010","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/jcpt.13246","article-title":"Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis","volume":"45","author":"J Barochiner","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"pone.0248652.ref011","article-title":"The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis","author":"Y Wang","year":"2020","journal-title":"J Med Virol"},{"key":"pone.0248652.ref012","unstructured":"World Health Organization. Clinical management of COVID-19. World Health Organization. 2020; WHO\/2019-nCoV\/clinical\/2020.5."},{"issue":"417","key":"pone.0248652.ref013","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/01621459.1992.10475190","article-title":"Generalized collinearity diagnostics","volume":"87","author":"J Fox","year":"1992","journal-title":"Journal of the American Statistical Association"},{"issue":"3","key":"pone.0248652.ref014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1214\/ss\/1032280214","article-title":"Bootstrap confidence intervals","volume":"11","author":"TJ DiCiccio","year":"1996","journal-title":"Statist Sci"},{"issue":"3","key":"pone.0248652.ref015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<313::AID-SIM370>3.0.CO;2-K","article-title":"Bootstrap confidence intervals for the sensitivity of a quantitative diagnostic test","volume":"19","author":"RW Platt","year":"2000","journal-title":"Stat Med"},{"issue":"12","key":"pone.0248652.ref016","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: A retrospective Italian cohort study of 43,000 patients","volume":"43","author":"G Trifir\u00f2","year":"2020","journal-title":"Drug Saf"},{"issue":"2","key":"pone.0248652.ref017","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"EL Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"pone.0248652.ref018","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"J Li","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"pone.0248652.ref019","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ejhf.1924","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust","volume":"22","author":"DM Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"pone.0248652.ref020","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: A nationwide population-based cohort study","volume":"71","author":"SY Jung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0248652.ref021","article-title":"Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study","author":"M Lafaurie","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"pone.0248652.ref022","doi-asserted-by":"crossref","first-page":"e0235248","DOI":"10.1371\/journal.pone.0235248","article-title":"Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, in a sample of infected Italian citizens","volume":"15","author":"F Bravi","year":"2020","journal-title":"PLoS One"},{"key":"pone.0248652.ref023","first-page":"1074248420976279","article-title":"Association of angiotensin-converting enzyme inhibitors and angiotensin II blockers with severity of COVID-19: A multicenter, prospective study","author":"HA Hakeam","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"3","key":"pone.0248652.ref024","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect ofdiscontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A randomized clinical trial","volume":"325","author":"RD Lopes","year":"2021","journal-title":"JAMA"},{"journal-title":"The Journal of Clinical Hypertension","article-title":"Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study","author":"AZ Bauer","key":"pone.0248652.ref025"},{"key":"pone.0248652.ref026","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjcard.2020.07.007","article-title":"Angiotensin converting enzyme inhibitor and angiotensin II receptor blocker use among outpatients diagnosed with COVID-19","volume":"132","author":"DJ Bae","year":"2020","journal-title":"Am J Cardiol"},{"issue":"8","key":"pone.0248652.ref027","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","article-title":"Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome","volume":"222","author":"KW Lam","year":"2020","journal-title":"J Infect Dis"},{"key":"pone.0248652.ref028","article-title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: A cohort study","author":"S Dublin","year":"2020","journal-title":"Am J Hypertens"},{"issue":"Pt A","key":"pone.0248652.ref029","first-page":"21","article-title":"The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","volume":"125","author":"XC Li","year":"2017","journal-title":"Pharmacological research"},{"issue":"1","key":"pone.0248652.ref030","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1038\/s41467-020-19145-6","article-title":"ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs","volume":"11","author":"IT Lee","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0248652.ref031","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence?","author":"AB Patel","year":"2020","journal-title":"JAMA"},{"key":"pone.0248652.ref032","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","author":"M Vaduganathan","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"pone.0248652.ref033","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"K Kuba","year":"2005","journal-title":"Nature Medicine"},{"issue":"20","key":"pone.0248652.ref034","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"CM Ferrario","year":"2005","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:34:06Z","timestamp":1616088846000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248652"}},"subtitle":[],"editor":[{"given":"Yu Ru","family":"Kou","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248652","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}